Neuromuscular disorders : NMD · 2018
Spinal muscular atrophy with respiratory distress type 1: A multicenter retrospective study.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Viguier Agnès, Lauwers-Cances Valérie, Cintas Pascal, Manel Véronique, Peudenier Sylviane, Desguerre Isabelle, Quijano-Roy Susana, Vanhulle Catherine, Fradin Mélanie, Isapof Arnaud, Jokic Michaël, Mathieu-Dramard Michèle, Dieterich Klaus, Petit Florence, Magdelaine Corinne, Giuliano Fabienne, Gras Domitille, Haye Damien, Nizon Mathilde, Magen Maryse, Bieth Eric, Cances Claude
Аннотация
Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is a rare autosomal recessive neuromuscular disorder characterized by progressive motor and respiratory decline during the first year of life. Early and late-onset cases have recently been reported, although not meeting the established diagnostic criteria, these cases have been genotyped. We thus conducted a national multicenter observational retrospective study to determine the prognosis of children with SMARD1 according to their phenotype. We recorded all known French pediatric cases with mutations identified on the immunoglobulin μ-binding protein 2 gene and the presence of respiratory symptoms. Thirty centers provided 22 observations. A diaphragmatic palsy was diagnosed 1.5 months (p = 0.02) after first respiratory symptoms, and hypotonia preceded areflexia by 4 months (p = 0.02). Early onset of symptoms leading to specialist consultation before the age of 3 months was associated with a significantly worse prognosis (p < 0.01). Among the 6 patients who were still alive, all were tracheostomized. Only one case survived beyond 2 years without artificial ventilation. The remaining patients died at a median age of 7 months. Our results may help pediatricians to provide medical information to parents and improve the decision-making process of setting up life support.